Literature DB >> 11771666

Expansile skeletal hyperphosphatasia is caused by a 15-base pair tandem duplication in TNFRSF11A encoding RANK and is allelic to familial expansile osteolysis.

Michael P Whyte1, Anne E Hughes.   

Abstract

Expansile skeletal hyperphosphatasia (ESH) is a singular disorder characterized in the year 2000 in a mother and daughter with early-onset deafness, premature loss of teeth, progressive hyperostotic widening of long bones causing painful phalanges in the hands, accelerated bone remodeling, and episodic hypercalcemia likely inherited as a highly penetrant, autosomal dominant trait. Absence of large osteolytic lesions with cortical thinning in major long bones, together with bouts of hypercalcemia, indicated that ESH is not a variant of familial expansile osteolysis (FEO). Here, we investigated the molecular basis of ESH after three families with FEO were reported to have an identical 18-base pair tandem duplication (84dup18) in the signal peptide sequence of the TNFRSF11A gene that encodes receptor activator of nuclear factor-kappaB (RANK). We find that ESH is caused by a remarkably similar 15-base pair tandem duplication (84dup15) in TNFRSF11A. Hence, ESH and FEO are allelic diseases and ESH, like FEO, probably reflects increased activity in the skeleton of the RANK target, nuclear factor-kappaB (NF-kappaB).

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11771666     DOI: 10.1359/jbmr.2002.17.1.26

Source DB:  PubMed          Journal:  J Bone Miner Res        ISSN: 0884-0431            Impact factor:   6.741


  40 in total

Review 1.  New knowledge on critical osteoclast formation and activation pathways from study of rare genetic diseases of osteoclasts: focus on the RANK/RANKL axis.

Authors:  J C Crockett; D J Mellis; D I Scott; M H Helfrich
Journal:  Osteoporos Int       Date:  2010-05-11       Impact factor: 4.507

2.  RANK ligand and the regulation of skeletal remodeling.

Authors:  Norman H Bell
Journal:  J Clin Invest       Date:  2003-04       Impact factor: 14.808

3.  Paget's disease: epidemiology and pathophysiology.

Authors:  Margaret Seton
Journal:  Curr Osteoporos Rep       Date:  2008-12       Impact factor: 5.096

4.  Panostotic expansile bone disease with massive jaw tumor formation and a novel mutation in the signal peptide of RANK.

Authors:  Anne L Schafer; Steven Mumm; Ivan El-Sayed; William H McAlister; Andrew E Horvai; Andrea M Tom; Edward C Hsiao; Frederick V Schaefer; Michael T Collins; Mark S Anderson; Michael P Whyte; Dolores M Shoback
Journal:  J Bone Miner Res       Date:  2014-04       Impact factor: 6.741

5.  Early onset Paget's disease of bone caused by a novel mutation (78dup27) of the TNFRSF11A gene in a Chinese family.

Authors:  Yao-hua Ke; Hua Yue; Jin-wei He; Yu-juan Liu; Zhen-lin Zhang
Journal:  Acta Pharmacol Sin       Date:  2009-07-06       Impact factor: 6.150

Review 6.  Osteoimmunology: interactions of the bone and immune system.

Authors:  Joseph Lorenzo; Mark Horowitz; Yongwon Choi
Journal:  Endocr Rev       Date:  2008-05-01       Impact factor: 19.871

7.  Paget's Disease of Bone: A Review of Epidemiology, Pathophysiology and Management.

Authors:  Joseph L Shaker
Journal:  Ther Adv Musculoskelet Dis       Date:  2009-04       Impact factor: 5.346

Review 8.  Sclerosing bone dysplasias: leads toward novel osteoporosis treatments.

Authors:  Igor Fijalkowski; Eveline Boudin; Geert Mortier; Wim Van Hul
Journal:  Curr Osteoporos Rep       Date:  2014-09       Impact factor: 5.096

Review 9.  Paget's disease of bone-genetic and environmental factors.

Authors:  Frederick R Singer
Journal:  Nat Rev Endocrinol       Date:  2015-08-18       Impact factor: 43.330

10.  RANK, RANKL and osteoprotegerin in bone biology and disease.

Authors:  H L Wright; H S McCarthy; J Middleton; M J Marshall
Journal:  Curr Rev Musculoskelet Med       Date:  2009-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.